Tumour-induced osteomalacia due to residual benign glomangioma

BMJ Case Rep. 2022 Nov 10;15(11):e250237. doi: 10.1136/bcr-2022-250237.


Tumour-induced osteomalacia (TIO) is a rare paraneoplastic syndrome. The constellation of findings of unprovoked fractures, hypophosphataemia, urinary phosphate wasting and a negative genetic evaluation suggest a TIO diagnosis. Tumours leading to TIO are often small and difficult to localise using standard imaging studies. The 68Ga-DOTATATE CT/positron emission tomography, a somatostatin receptor imaging modality, is the radiographical study of choice for localisation. It is highly sensitive and specific since tumours that cause oncogenic osteomalacia have been shown to express somatostatin receptors. Complete surgical resection is the treatment of choice; however, it may not always be feasible. Burosumab, a human anti-fibroblast growth factor-23 monoclonal antibody, is a therapeutic option in cases of unresectable TIO to normalise phosphorus levels and improve fracture healing. Our patient was initiated on burosumab, which led to healing of his fractures and profound symptomatic improvement of his pain. TIO is often undiagnosed for many years, leading to significant patient morbidity.

Keywords: calcium and bone; drugs: endocrine system; endocrinology; musculoskeletal and joint disorders.

Publication types

  • Case Reports

MeSH terms

  • Fractures, Bone* / complications
  • Glomus Tumor*
  • Humans
  • Neoplasms*
  • Osteomalacia* / diagnosis
  • Paraneoplastic Syndromes* / diagnosis
  • Tomography, X-Ray Computed / methods


  • copper dotatate CU-64

Supplementary concepts

  • Oncogenic osteomalacia